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It has been suggested that there are hepatic receptors for sodium chloride 1) glucose 2，3)， amino 
acids 4-7)， and osmotic pressure 8) Several studies have shown that the receptors for glucose or 
arginine in the hepato-portal system exert a reflex regulation of the pancreatic neuroendocrine 
system and modulate insulin secretion 2，4-6，9) The vagal efferent pathways may be involved in the 
pancreatic neuroendocrine system via the afferent pathways from the hepatic neural metabolic 
receptors. Thus， hepatic glucose receptor is suggested to stimulate insulin secretion 2) and hepatic 
arginine receptor is suggested to inhibit insulin secretion via cholinergic mechanisms 4，6) However， 
the neural modulation of hepato-portal glucose-or arginine-receptors in insulin secretion remains to 
be fully elucidated. In order to clarify this issue， the effect of cholinergic blockade or adrenergic 
blockade on insulin secretion in response to intraportal glucose or arginine was investigated in the 
rat. 
MATERIALS AND METHODS 
Animals 
Male Wistar albino rats weighing approximately 250g were provided in this study， After an 
overnight fasting， the rats were anesthetized with intraperitoneal pentobarbital sodium (30 mg/kg)， 
and the body temperature of the rat was maintained at 370C on the hot plate throughout the study， 
Thirty minutes after the abdomen was opened， the following examinations were performed. 
Glucose infusion test 
To obtain similar levels of arterial blood glucose， glucose in a 20% solution was bolus infused into 
the femoral vein at a dose of O. 5g/kg (peripheral stimulation) or into the portal vein at a dose of 
0.6g/kg (portal stimulation). The blood specimen for blood glucose measurement (0， 1ml) was drawn 
from the abdominal aorta and the blood specimen for insulin measurement (0. 5ml) was drawn from 
the portal vein at 0， 2， 5， and 10 min. In one series of glucose infusion tests， two rats were used 
to avoid the influence of hypovolemia， Blood specimens were drawn from one rat at 0 and 5， and 
from the other rat at 2 and 10 min， 
Arginine infusion test 
Arginine (0. 5g/kg in a 10覧 L-argininesolution) was bolus infused into the femoral vein 
(peripheral stimulation) or portal vein (portal stimulation)， and the blood specimen for blood 
glucose measurement was drawn from the abdominal aorta and the blood specimen for insulin 
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measurement was drawn from the portal vein at 0， 5， and 10 min. 
Preadministration of atropine， propranolol， or atenolol 
Atropine sulphate (lmg/kg， Tanabe Seiyaku， Osaka， ]apan) ， propranolol hydrochloride (0.5mg/kg， 
ICI Pharma， Osaka， ]apan)， or atenolol hydrochloride (50mg/kg， Sigma Chemical Co.， Missouri， 
AZ) was administered subcutaneously 30min before the glucose or arginine infusion test. 
Measurements 
Blood glucose concentration was measured by a glucose oxidase method. Plasma insulin was 
assayed by radioimmunoassay using rat insulin standard， of which sensitivity was estimated to be 
2μU/ml. Intra-and interassay coefficients of variation were 5 and 10%. 
Statistics of data 
The data were expressed as the mean :!: SD・. Analysis of variance and two-tailed Student' s 
non-paired t test were applied. 
RESULTS 
Glucose infusion test 
As shown in Fig. 1， arterial blood glucose level and portal plasma insulin concentration were not 
significantly different between peripheral stimulation and portal stimulation. 
Arginine infusion test 
As shown in Fig. 2， blood glucose level and plasma insulin concentration were not significantly 
different between peripheral stimulation and portal stimulation. 
Glucose infusion test after treatment with blockades 
As shown in Figs. 3， 4， and 5， blood glucose responses were not significantly changed by the 
preadministration of any blockade. In atropine-or atenolol-treated rats， insulin concentration was 
almost similar in peripheral and portal stimulation (Figs. 3 and 5). In propranolol-treated rats， 
insulin concentration was significantly (p<0.05) higher in portal stimulation (78土 26and 115土
25μU/ml) than in peripheral stimulation (48士 13and 46土 14μU/ml)at 5 and 10 min， 
respectively (Fig. 4). 
Arginine infusion test after treatment with blockades 
As shown in Figs. 6， 7， and 8， blood glucose responses were not significantly changed by the 
preadministration of any blockade. In atropine-treated rats， insulin concentration was almost similar 
in peripheral and portal stimulation (Fig. 6). In propranolol-treated rats， insulin concentrations in 
portal stimulation (124土 50and 121 :!: 47μU/ml) were significantly (p<0.05) higher than those 
in peripheral stimulation (60 :!: 20 and 25 :!: 5μU/ml) at 5 and 10 min， respectively (Fig. 7). In 
atenolol-treated rats， insulin concentration was significantly (p < 0.05) higher in portal stimulation 
(128士 40μU/ml)than in peripheral stimulation (76主 22μU/ml)at 5 min (Fig. 8). 
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Fig. 7 Blood glucose and plasma insulin responses Fig. 8 Blood glucose and plasma insulin responses 
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The values are means ごと SD. The values are means土 SD.
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Portal sensor for glucose or arginine 49 
DISCUSSION 
In the present study， insulin concentration secreted after portal administration of glucose or 
arginine was not significantly different from that after peripheral administration of glucose or 
arginine， and atropine pretreatment did not significantly change the insulin response to portal 
glucose or argiriine. These results suggest that cholinergic mechanisms have nO importan t role in 
insulin secretion in response to portal glucose or arginine. The present results were contradictory to 
the results of previous studies. Lee and Miller 9) and Okazaki et al. 10) found that hepatic vagotomy 
decreases insulin respOnse (in the arterial blood or jugular vein) to intraperitoneal glucose 
administration. Tanaka et al. 4.6) sUggested that the hepatic branch of the vagus nerve contains 
arginine-sensitive afferent fibers which sense portal arginine concentrations and send signals to the 
brainstem centers， which then inhibit the activities of the vagal efferent pancreatic neuroendocrine 
system after intraperitoneal arginine stimulation. The reason for the discrepancy in the results is 
unclear. Glucose or arginine was infused directly into the portal vein， and portal insulin concentration 
was measured to avoid the influence of hepatic insulin extraction in the present study. This may 
explain the difference in the results. 
It is generally accepted that s -adrenergic antagonist decreases insulin secretion induced by a 
variety of stimuli 11.12) In the present study， the glucose-induced insulin secretion to portal 
stimulation was significantly enhanced by the preadministration of propranolol， and arginine-induced 
insulin secretion to portal stimulation was also significantly enhanced by the preadministration of 
propranolol or atenolol. There have been only a few reports regarding the role of the adrenergic 
system in hepato-portal glucose-or arginine-receptors. Tanaka et al. 6) suggested that sympathetic 
pathways are not involved in the arginine sensor-mediated pancreatic neuroendocrine system. 
However， the present results suggest that the s -adrenergic mechanisms have some role in insulin 
response to portal stim ulation of glucose or arginine. Namely， hepato-portal receptors for glucose 
inhibit insulin secretion via s 2-adrenergic mechanisms and receptors for arginine also inhibit insulin 
secretion via s l-and s 2-adrenergic mechanisms. In the study of Tana1王
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SUMMARY 
To elucidate the possible role of the hepato-portal system in glucose-or arginine-induced insulin 
secretion， insulin response to intraportal (portal stimulation) or intravenous (peripheral stimulation) 
glucose or arginine infusion was investigated in the rat. The glucose-or arginine-induced insulin 
secretion was not significantly different between portal stimulation and peripheral stimulation. The 
glucose-or arginine-induced insulin secretion was significantly higher in portal stimulation than in 
peripheral stimulation after propranolol pretreatment (0. 5mg/kg， sc). The glucose-induced insulin 
release was not significantly changed by atenolol pretreatment. However， the arginine-induced 
insulin release was significantly higher in portal stimulation than in peripheral stimulation after 
atenolol pretreatment (50mg/l王g，sc). 
These results suggest that there are receptors for glucose and arginine in the hepato-portal 
system， and that the hepato-portal receptors for glucose and arginine inhibit insulin secretion via 
s -adrenergic mechanisms. 
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